ELVN — ENLIVEN THERAPEUTICS INC COM

Ownership history in Parallel Advisors, LLC  ·  4 quarters on record

This page tracks every 13F SEC filing in which Parallel Advisors, LLC reported a position in ENLIVEN THERAPEUTICS INC COM (ELVN). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q3 ADDED 491 +463 +1653.6% 0.00% $10K $20.47
2025 Q2 ADDED 28 +18 +180.0% 0.00% $562 $20.06
2025 Q1 ADDED 10 +6 +150.0% 0.00% $197 $19.68
2024 Q4 INITIATED 4 — — 0.00% $90 $22.50
% of Fund (quarterly)    ELVN price (monthly, adj. close)

Other funds also holding ELVN

As of 2025 Q4 — sorted by position size

Commodore Capital LP 3Y 4.81% Fairmount Funds Management LLC 3Y 4.35% 5AM Venture Management, LLC 3Y 3.74% ORBIMED ADVISORS LLC 3Y 7Y 2.5% VR Adviser, LLC 3Y 2.45% Vestal Point Capital, LP 2.01% Novo Holdings A/S 3Y 7Y 1.77% Exome Asset Management LLC 1.64% Patient Square Capital LP 3Y 1.02% SPHERA FUNDS MANAGEMENT LTD. 3Y 7Y 0.68%
← Back to Parallel Advisors, LLC Holdings